$1.54 Billion is the total value of Cormorant Asset Management, LP's 65 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 240.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $53,962,000 | +242.9% | 660,000 | +46.7% | 3.51% | +201.0% |
| TSRO | Buy | TESARO INC | $48,763,000 | +99.4% | 1,250,000 | +127.3% | 3.17% | +75.1% |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $43,447,000 | – | 1,486,898 | +100.0% | 2.82% | – |
| QTNT | Buy | QUOTIENT LTD | $36,618,000 | +6.3% | 4,850,000 | +13.0% | 2.38% | -6.7% |
| OMER | New | OMEROS CORPcall | $27,752,000 | – | 1,136,900 | +100.0% | 1.80% | – |
| ZGNX | New | ZOGENIX INC | $24,800,000 | – | 500,000 | +100.0% | 1.61% | – |
| TSRO | New | TESARO INCcall | $19,505,000 | – | 500,000 | +100.0% | 1.27% | – |
| INCY | Buy | INCYTE CORP | $17,961,000 | +34.0% | 260,000 | +30.0% | 1.17% | +17.6% |
| ZLAB | Buy | ZAI LAB LTDadr | $15,743,000 | +103.2% | 808,166 | +142.6% | 1.02% | +78.5% |
| ZGNX | New | ZOGENIX INCcall | $12,400,000 | – | 250,000 | +100.0% | 0.81% | – |
| RUBY | New | RUBIUS THERAPEUTICS INC | $8,749,000 | – | 364,559 | +100.0% | 0.57% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $8,558,000 | – | 1,271,687 | +100.0% | 0.56% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $8,135,000 | – | 500,000 | +100.0% | 0.53% | – |
| REPL | New | REPLIMUNE GROUP INC | $7,531,000 | – | 467,792 | +100.0% | 0.49% | – |
| YMAB | New | Y MABS THERAPEUTICS INC | $5,312,000 | – | 200,000 | +100.0% | 0.34% | – |
| AKCA | New | AKCEA THERAPEUTICS INCput | $3,502,000 | – | 100,000 | +100.0% | 0.23% | – |
| ARQL | New | ARQULE INC | $1,698,000 | – | 300,000 | +100.0% | 0.11% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.